Once-weekly teriparatide reduces serum sclerostin levels in postmenopausal women with osteoprosis
| Autor: | Yukinori Tamura, Terumasa Ikeda, Masao Akagi, Hiroshi Kaji |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Genetic Markers
musculoskeletal diseases medicine.medical_specialty Bone density Osteocalcin Osteoporosis Urology Lumbar vertebrae Drug Administration Schedule 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Bone Density Teriparatide medicine Humans Orthopedics and Sports Medicine Prospective Studies Osteoporosis Postmenopausal Adaptor Proteins Signal Transducing Aged Femoral neck Aged 80 and over Bone mineral 030222 orthopedics Lumbar Vertebrae Bone Density Conservation Agents biology Femur Neck business.industry musculoskeletal system medicine.disease medicine.anatomical_structure chemistry Bone Morphogenetic Proteins biology.protein Sclerostin Female Surgery business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Journal of Orthopaedic Science. 24:532-538 |
| ISSN: | 0949-2658 |
| DOI: | 10.1016/j.jos.2018.10.028 |
| Popis: | Once-weekly teriparatide treatment is widely used in the treatment of osteoporosis in Japan but the mechanisms causing the increase in bone mineral density (BMD) of the lumbar spine remain unknown. Methods: This prospective study examined the effects of once-weekly teriparatide treatment on the serum levels of sclerostin, osteocalcin, and bone formation markers as well as BMD of the lumbar spine and femoral neck in 32 postmenopausal women with osteoporosis. Results: The mean age of subjects was 76.3 ± 7.0 years old. Teriparatide significantly reduced serum sclerostin levels at 12 and 18 months in postmenopausal women with osteoporosis, and significantly increased serum osteocalcin levels at 3,12 and 18 months and PINP levels at 1 and 3 months, respectively. Teriparatide treatment significantly increased BMD of the lumbar spine at 6, 12, and 18 months, but did not affect BMD of the femoral neck. Examination of the relationships between percent changes in bone metabolic indices and BMD of the lumbar spine during the teriparatide treatment showed serum sclerostin changes at 3 months were negatively correlated with BMD changes of the lumbar spine at 6, 12, and 18 months. Serum osteocalcin changes were not correlated with BMD changes in the lumbar spine at 12 months. Conclusions: The present study showed that once-weekly teriparatide treatment reduced serum sclerostin levels in postmenopausal women with osteoporosis. The effects of teriparatide on sclerostin may be associated with the response of the BMD of the lumbar spine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|